Here’s Why the Novavax Vaccine May Have to Wait for FDA Authorization

1 min read

Novavax‘s (NASDAQ: NVAX) investigational coronavirus vaccine is on its way to the big finish line: regulatory authorization. The company recently reported positive phase 3 data. And now, regulatory agencies in the U.S., Europe, the U.K., and Canada are conducting rolling reviews. If Novavax follows in the footsteps of more advanced rivals Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA), we could imagine a vaccine on the market in a matter of weeks.

But one element may hold Novavax back in the U.S. While the U.S. Food and Drug Administration (FDA) may still grant the candidate emergency use authorization (EUA), the agency might wait a bit longer to make its decision. Let’s take a closer look at why the FDA might take its time on this one — and what it means for Novavax investors.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Forget AMC and GameStop: These 4 Growth Stocks Can Triple in Value

Next Story

Here’s Why You Can’t Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

Latest from Blog